Product Overview

Warf 3 mg (Warfarin) is a prescription oral anticoagulant produced by Cipla Limited, a globally recognized pharmaceutical company with a strong reputation for quality manufacturing under WHO‑GMP standards. Each strip contains ten tablets, each delivering a precise 3 mg dose of warfarin sodium, a well‑studied vitamin K antagonist. The medication is indicated for the prevention of thromboembolic events in patients who are at increased risk for blood clot formation, including those with atrial fibrillation, a history of deep vein thrombosis (DVT), pulmonary embolism (PE), or who have undergone orthopedic surgeries such as total hip or knee replacement. The product is packaged for convenient daily administration and is intended for long‑term use under medical supervision.

What is Warf 3 mg (Warfarin)

Warfarin belongs to the class of vitamin K antagonists, which exert their therapeutic effect by blocking the enzymatic reduction of vitamin K epoxide. This inhibition prevents the γ‑carboxylation of several clotting factors — specifically factors II, VII, IX, and X — thereby diminishing the blood’s ability to form clots. The drug is administered orally and requires regular monitoring of the International Normalized Ratio (INR) to ensure that the anticoagulant effect remains within a therapeutic window. Genetic variations in the CYP2C9 and VKORC1 genes can significantly influence a patient’s response to warfarin, making pharmacogenomic testing a useful tool for personalized dosing.

Uses and Benefits

Warf 3 mg is primarily prescribed for the prophylaxis of venous and arterial thromboembolism. Clinical trials have demonstrated that chronic warfarin therapy can reduce the incidence of stroke by approximately 30–40 % in patients with non‑valvular atrial fibrillation. In addition, the medication is effective in preventing recurrent DVT and PE after an initial episode, and it is commonly used to reduce clot formation on artificial heart valves. The benefits of Warf 3 mg include:

• Highly adjustable dosing that allows clinicians to fine‑tune anticoagulation based on INR measurements.
• Extensive clinical experience spanning more than five decades, providing a robust evidence base for safety and efficacy.
• Manufactured by Cipla Limited, a company with a long history of producing affordable, quality‑assured generic medications.
• Packaged in a strip of ten tablets, which supports adherence by simplifying daily routines.
• Availability in a low‑strength 3 mg tablet, facilitating precise dose titration for patients who require lower anticoagulation levels.

Patients often experience improved quality of life because the risk of clot‑related complications — such as stroke, systemic embolism, and post‑thrombotic syndrome — is markedly reduced.

How It Works

The pharmacological action of warfarin centers on its role as a competitive inhibitor of the enzyme complex vitamin K epoxide reductase (VKORC1). This enzyme is essential for the regeneration of reduced vitamin K, a cofactor required for the carboxylation of several clotting factors. By occupying the active site of VKORC1, warfarin prevents the recycling of vitamin K, leading to a decrease in the synthesis of functional clotting proteins. The net effect is a prolongation of the clotting time, which is quantified by measuring the INR. Because warfarin’s effect is indirect and dependent on the turnover of clotting factors, the anticoagulant effect develops gradually over several days and persists for several days after discontinuation.

Pharmacokinetic considerations include variable oral bioavailability, extensive plasma protein binding, and hepatic metabolism primarily via the cytochrome P450 enzyme CYP2C9. Drug–drug interactions — such as those with antibiotics, antifungals, and certain herbal supplements — can alter warfarin metabolism and necessitate dose adjustments. Consequently, clinicians often recommend periodic INR checks when initiating or modifying concomitant medications.

Dosage Guidelines

Warfarin therapy is highly individualized, and the appropriate dose is determined by sequential INR monitoring. The typical starting dose of Warf 3 mg ranges from 2.5 mg to 5 mg per day, but the exact amount depends on factors such as age, body weight, hepatic function, and concomitant medications. After the initial dose, the INR is usually checked within 5–7 days, and the dose is adjusted by 0.5 mg to 1 mg increments based on the measured INR. The target INR for most indications — such as atrial fibrillation, DVT, and PE — is 2.0–3.0. For mechanical heart valve replacement, a higher target of 2.5–3.5 may be required.

Patients are advised to take the tablet at the same time each day, with or without food, and to maintain a consistent intake of vitamin K‑rich foods. Sudden increases or decreases in dietary vitamin K can shift the INR unpredictably. Alcohol consumption should be limited, as excessive intake can potentiate the anticoagulant effect and increase bleeding risk. If a dose is missed, the patient should not double the next dose; instead, the next scheduled dose should be taken as prescribed.

For detailed dosing algorithms, refer to the FDA prescribing information and consult a qualified healthcare professional.

Side Effects

Warfarin is generally well tolerated, but all patients should be aware of potential adverse effects. Common, mild side effects include minor bleeding (e.g., nosebleeds, gum bleeding), skin rash, and occasional hair loss. These symptoms often resolve without medical intervention.

Serious adverse events require prompt medical attention. The most critical concerns are major bleeding episodes, which may manifest as gastrointestinal bleeding (melena, hematochezia), hematuria, or intracranial hemorrhage. Signs such as sudden severe headache, visual changes, or unexplained bruising should trigger immediate contact with a physician. Additionally, warfarin can cause skin necrosis in rare cases, particularly in patients with underlying protein C deficiency, and may precipitate cholesterol emboli in extremities.

For a comprehensive overview of safety data, consult the MedlinePlus drug entry for warfarin.

Warnings and Precautions

Warfarin is contraindicated in individuals with active bleeding disorders, severe hepatic disease, or known hypersensitivity to the drug. Prior to initiation, a thorough medication reconciliation is essential to identify agents that may increase bleeding risk, such as non‑steroidal anti‑inflammatory drugs (NSAIDs), aspirin, and certain antibiotics (e.g., trimethoprim‑sulfamethoxazole). Pregnant and lactating women should avoid warfarin unless the benefits clearly outweigh the risks, as the drug can cross the placenta and affect fetal coagulation.

Before any surgical or invasive procedure, clinicians must evaluate the necessity of warfarin discontinuation. Typically, therapy is paused 5–7 days before the intervention to allow the INR to fall below 1.5, minimizing peri‑operative bleeding. However, bridge therapy with a short‑acting anticoagulant may be required for high‑risk patients, such as those with mechanical heart valves.

Storage instructions: Keep the strip at room temperature, away from moisture, heat, and direct sunlight. Ensure the medication is inaccessible to children and pets.

Frequently Asked Questions

Q: How long does it take for Warf 3 mg to start protecting against clots?
A: Warfarin begins to inhibit the synthesis of clotting factors within 24–48 hours, but a full therapeutic effect is usually evident after 3–5 days of consistent dosing, as reflected by an upward trend in the INR.

Q: Can I take Warf 3 mg with other medications?
A: Warfarin interacts with many drugs, including certain antibiotics (e.g., macrolides), antifungal agents, and herbal supplements like St. John’s wort. A complete medication review with a healthcare provider is essential before combining therapies.

Q: What INR range is considered therapeutic?
A: For most indications, the target INR is 2.0–3.0. Specific conditions, such as mechanical heart valve replacement, may require a higher target of 2.5–3.5. Your physician will determine the appropriate range for you.

Q: Is alcohol consumption safe while on Warf 3 mg?
A: Moderate alcohol intake may be permissible, but heavy or binge drinking can increase the risk of bleeding. Discuss any alcohol use with your doctor to determine a safe limit.

Q: How should Warf 3 mg be stored?
A: Store the strip at room temperature, away from moisture and direct sunlight. Keep the medication out of reach of children and pets.

For additional authoritative information, visit the National Institutes of Health, the U.S. Food and Drug Administration, or MedlinePlus.

Related Products

• Ciplox 750mg (Ciprofloxacin)
• Diclofenac SR 100 mg
• Reactin 50 mg (Diclofenac)
• Cromal Forte Eye Drop (Sodium Cromoglycate)
• Alendronic Acid 35 mg (Generic)
• Rizact 5 mg (Rizatriptan)
• Flunarizine 5 mg (Generic)
• Eliquis 2.5 mg (Apixaban)
• Warf 1 mg (Warfarin)
• Warf 2 mg (Warfarin)
• Mucinac 200 mg (Acetylcysteine)
• Temozolomide 20 mg (Generic)